Health-state utilities in liver disease: A systematic review

被引:139
作者
McLernon, David J. [1 ]
Dillon, John [2 ]
Donnan, Peter T. [1 ]
机构
[1] Univ Dundee, Tayside Ctr Gen Practice, Hlth Informat Ctr, Dundee DD1 4HN, Scotland
[2] Univ Dundee, Dept Digest Dis & Clin Nutr, Dundee DD1 4HN, Scotland
关键词
health-state utility; liver disease; systematic review; meta-analysis; hepatitis C;
D O I
10.1177/0272989X08315240
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Objectives. Health-state utilities are essential for cost-utility analysis. Few estimates exist for liver disease in the literature. The authors' aim was to conduct a systematic review of health-state utilities in liver disease, to look at the variation of study designs used, and to pool utilities for some liver disease states. Methods. A search of MEDLINE, EMBASE, and CINAHL from 1966 to September 2006 was conducted including key words related to liver disease and utility measuring tools. Articles were included if health-state utility tools or expert opinion were used. Variance-weighted mean utility estimates were pooled using metaregression adjusting for disease state and utility assessment method. Results. Thirty studies measured utilities of liver diseases/disease states. Half of these estimated utilities for hepatitis viruses: hepatitis A (n=1), hepatitis B (n=4), and hepatitis C (n=10). Others included liver transplant (n=6) and chronic liver disease (n= 5) populations. Twelve utility methods were used throughout. The EQ-5D (n=10) was most popular method, followed by visual analogue scale (n=9), time tradeoff (n=6), and standard gamble (n=4). Respondents were patients (n=16), an expert panel (n=10), non-liver diseases adults (n=2), patient and expert (n=1), and patient and healthy adult (n=1). Type of perspective included community (n=21), patient (n=4), and both (n=5). The pooled mean estimates in hepatitis C with moderate disease, compensated cirrhosis, decompensated cirrhosis, and post-liver transplant using the EQ-5D were 0.75, 0.75, 0.67, and 0.71, respectively. The change in these utilities using different methods were -0.07 (visual analogue scale), -0.01 (health utilities index version 3), +0.04 (standard gamble), +0.08 (health utilities index version 2), +0.12 (time tradeoff), and +0.15 (standard gamble-transformed visual analogue scale). Conclusions. The authors have created a valuable liver disease-based utility resource from which researchers and policy makers can easily view all available utility estimates from the literature. They have also estimated health-state utilities for major states of hepatitis C.
引用
收藏
页码:582 / 592
页数:11
相关论文
共 52 条
  • [1] Screening for hemochromatosis in children of homozygotes: Prevalence and cost-effectiveness
    Adams, PC
    Kertesz, AE
    Valberg, LS
    [J]. HEPATOLOGY, 1995, 22 (06) : 1720 - 1727
  • [2] [Anonymous], 2001, SYSTEMATIC REV HLTH, DOI DOI 10.1002/9780470693926
  • [3] Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C
    Bennett, WG
    Inoue, Y
    Beck, JR
    Wong, JB
    Pauker, SG
    Davis, GL
    [J]. ANNALS OF INTERNAL MEDICINE, 1997, 127 (10) : 855 - +
  • [4] The estimation of a preference-based measure of health from the SF-36
    Brazier, J
    Roberts, J
    Deverill, M
    [J]. JOURNAL OF HEALTH ECONOMICS, 2002, 21 (02) : 271 - 292
  • [5] A review and meta-analysis of prostate cancer utilities
    Bremner, Karen E.
    Chong, Christopher A. K. Y.
    Tomlinson, George
    Alibhai, Shabbir M. H.
    Krahn, Murray D.
    [J]. MEDICAL DECISION MAKING, 2007, 27 (03) : 288 - 298
  • [6] Health-related quality of life following liver transplantation
    Bryan, S
    Ratcliffe, J
    Neuberger, JM
    Burroughs, AK
    Gunson, BK
    Buxton, MJ
    [J]. QUALITY OF LIFE RESEARCH, 1998, 7 (02) : 115 - 120
  • [7] Health status versus utilities of patients with end-stage liver disease
    Bryce, CL
    Angus, DC
    Switala, JA
    Roberts, MS
    Tsevat, J
    [J]. QUALITY OF LIFE RESEARCH, 2004, 13 (04) : 773 - 782
  • [8] Chong CAKY, 2003, AM J GASTROENTEROL, V98, P630, DOI [10.1016/S0002-9270(02)06054-9, 10.1111/j.1572-0241.2003.07332.x]
  • [9] Variation in the estimation of quality-adjusted life-years by different preference-based instruments
    Conner-Spady, B
    Suarez-Almazor, ME
    [J]. MEDICAL CARE, 2003, 41 (07) : 791 - 801
  • [10] Quality of life and cognitive function in hepatitis C at different stages of liver disease
    Córdoba, J
    Flavìa, M
    Jacas, C
    Sauleda, S
    Esteban, JI
    Vargas, V
    Esteban, R
    Guardia, J
    [J]. JOURNAL OF HEPATOLOGY, 2003, 39 (02) : 231 - 238